Personalised Cancer Care intelligence
In partnership with Public Health England (PHE) between 2015-2020, we have produced numerous innovative analyses of the cancer prevalent population, both regionally and nationally.
In 2018, the TCST/PHE Partnership published the first cancer prevalence dashboard for all of England. The dashboard shows demographic data by sex, age, ethnicity, deprivation, location. The dashboard also includes time since diagnosis and forecasted growth of cancer prevalence by 2030. Other analysis was conducted on the prevalence of subsequent primary cancers amongst those living with and beyond a cancer diagnosis at the end of 2016.
TCST has also co-produced regional KPIs and data definitions for national personalised cancer care interventions, including healthcare and support plans (holistic needs assessments), treatment summaries, health & wellbeing interventions, patient initiated follow up (also known as personalised stratified follow up). These were refreshed in March 2020 and updated following COVID-19 in July 2020.
Together with, Tower Hamlets CCG and Tower Hamlets Clinical Effectiveness Group TCST produced guidance on clinical coding of cancer in primary care. This describes comparative analysis between national cancer registry data and GP practice registry data in England. The analysis showed that there were more than 18,000 people in London who have a diagnosis of cancer but are not recorded on a primary care practice register. The guidance also outlines how Tower Hamlets identified an issue with primary care coding for cancer patients and what they have done to ‘cleanse’ GP practice registers using the EMIS clinical system.
The TCST/PHE partnership has researched the demographic variation of people living in London with serious co-morbidities (that involved an inpatient stay) at the time of their cancer diagnosis. The Partnership’s Charlson Comorbidity Index analysis was based on the point scoring system that represents the presence of specific associated comorbid conditions at or around the time of diagnosis of cancer.
The TCST/PHE Partnership also created a Cancer and last 90 days of life dashboard that shows hospital use and cancer treatment for people diagnosed with cancer in London, where cancer was listed as the underlying cause of death.
TCST/PHE Partnership has presented at several national and international conferences since 2015. You can find our poster presentations below:
- Zalin A et al (2020), “2017 Cancer Prevalence Dashboard for London”, British Journal of General Practice Research Conference 2020, British Journal of General Practice Vol. 70, Issue suppl 1 June 2020, UK
- Jose S et al (2018), “Comparison of cancer prevalence data sources: National cancer registry and primary care registers”, PHE Outcomes Conference, UK
- Loughran et al (2017), “Understanding the current cancer population in England: detailed prevalence estimates”, National Cancer Data & Outcomes Conference, UK
- Loughran et al (2017), “Association of prevalence and co-morbidities at diagnosis for those living with and beyond cancer”, PHE Outcomes Conference, UK
- Loughran et al (2017), “Prevalence of subsequent primary tumours with demographic variation for those living with cancer in London”, PHE Outcomes Conference, UK
- Loughran et al (2017), Understanding the current cancer population in England: detailed prevalence estimates, PHE Outcomes Conference, UK
- Loughran et al (2017), “Understanding the current cancer population in England: detailed prevalence estimates at the end of 2015“, 39th Annual International Association of Cancer Registry Conference, p92, Utrecht, the Netherlands,